INTRODUCTION:The present study assessed the impact of the disposable Simplera Sync™ sensor with the MiniMed™ 780G (MM780G) advanced hybrid closed-loop (AHCL) system on type 1 diabetes (T1D) glycemic metrics, insulin delivery, and safety. MATERIALS AND METHODS:Youths (aged 7-17 years) and adults (aged 18-80 years) with T1D were enrolled in this single-arm, nonrandomized study at 24 sites in the United States. Participants began with an ∼2-week run-in period where hybrid closed-loop (HCL; auto basal only) or open-loop insulin delivery was used, followed by an ∼3-month study period with AHCL activated. Glycemic outcomes and insulin delivery during the last 6-7 weeks of the study, when settings were optimized at investigator's discretion, were compared with the run-in. Glycemic outcomes with the use of recommended optimal settings (ROS, 100 mg/dL glucose target with a 2-h active insulin time) were explored. RESULTS:Time in automation was high (>93%) and mean time in range (TIR) increased from 54.4% ± 15.7% to 71.4% ± 9.9% (P < 0.001) in youths and from 66.5% ± 12.6% to 80.2% ± 8.1% (P < 0.001) in adults, primarily due to reduced time above range. Youths had a slight increase in time below range (TBR <70 mg/dL) from 1.6% ± 1.7% to 1.9% ± 1.4% (P < 0.001), while adults had no significant difference in TBR. For ROS users, TIR was 74.7% ± 9.3% in youths and 83.8% ± 7.4% in adults. Throughout the study ∼60% of total daily insulin dose was automated (auto basal and auto correction) in both cohorts. There were two cases of severe hypoglycemia and one episode of diabetic ketoacidosis (not related to the device). CONCLUSIONS:MM780G use with the Simplera Sync sensor is safe and demonstrated improved glycemic outcomes in both pediatric and adult participants with T1D, compared with the run-in period.
Background:Adequate glucose control is an important, yet a challenging task, in the early postoperative care after liver transplantation (LTx). Potential of continuous glucose monitoring (CGM) in this context had not been fully explored because of concerns about sensors' precision in critical care. Objectives:We initiated a trial to assess feasibility, accuracy, and benefit of CGM used in addition to standard blood glucose (BG) management. Design:Prospective randomized trial. Methods:Patients undergoing LTx were included and randomized to wearing (1) unblinded ("active") CGM which could help guiding insulin therapy, (2) blinded CGM serving as controls. Dexcom G6 was applied immediately after surgery, arterial BG values measured with blood gas analyzer served as reference and for calibration. We evaluated mean absolute relative difference (MARD), Diabetes Technology Society (DTS) Error Grid zones, bias, 15/15 agreement rate, evolvement of accuracy over time, and possible interfering factors. Fisher test, Mann-Whitney test, DTS software, and linear mixed model were used for statistical analysis. Results:We included 155 LTx recipients, 13 were excluded (1 died during surgery, 12 experienced sensor failure-6 from each group), data from 142 patients (80 in active and 62 in blinded CGM group) were analyzed. Overall, MARD was 9.1% in active and 10.7% in the blinded group (p < 0.0001). DTS error grid in active group had shown 90% in zone A versus 85.3% in the blinded group. These results were consistent for reference glucose ranges 3.9-10 mmol/L and above 10 mmol/L, with less precision in the low ranges (these values were however rare). Sensor accuracy peaked on days 2-3 and deteriorated over time with significant worsening from day 7 on in both groups. Conclusion:Our study demonstrates feasibility and acceptable accuracy of CGM comparable to reports from the outpatient care. We believe this could be attributed to sensor calibration, reflected by more favorable outcomes in the active CGM group. In addition, we demonstrate decline in accuracy over time, suggesting their use in critical care could be limited to less days to secure sufficient reliability. Trial registration:This study is part of an ongoing prospective trial registered on ClinicalTrials.gov (NCT05585801) and was registered on October 12, 2022.
Abstract Introduction A recent randomized crossover trial compared a next-generation algorithm for Omnipod (Omnipod 6) with the first-generation Omnipod® 5 Automated Insulin Delivery System in a diverse population including adults (T1D/T2D) and children (T1D). Objectives This subgroup analysis assessed safety and efficacy within the vulnerable population of children with T1D who face elevated hypoglycemia risk. Methods This multicenter, randomized, crossover study compared Omnipod 6 at a 100mg/dL (5.6mmol/L) target with Omnipod 5 at a 110mg/dL (6.1mmol/L) target (4 weeks each) in current Omnipod 5 users. Users continued use of Omnipod 6 for an additional 4 weeks in a restricted bolus phase (goal of ≤3 boluses/day). Safety and efficacy outcomes were evaluated in children ages 2-<6 and 6-<14y. Results Children aged 2-<6y (n=29; age: 4±1y, baseline A1C: 7.0±0.8%) and 6-<14y (n=36; age: 11±2y, baseline A1C: 7.0±0.8%) with T1D were randomly assigned. The 100mg/dL target was used 82% and 95% of time in the 2-<6y and 6-<14y groups, respectively, with Omnipod 6. Time in tight range (70-140mg/dL) increased by 5.5% (+1.3h/d) with Omnipod 6 in those aged 6-<14y with no significant change in those aged 2-<6y. Time <54 and <70mg/dL remained low in both groups, meeting the non-inferiority margins of 0.75% and 3%, respectively (Table). A total of 63 children entered and completed the restricted bolus phase. TIR and TITR remained high with less boluses per day and algorithm insulin delivery increasing by a mean treatment group difference of 6% (4%, 8%) and 5% (2%, 7%), both p<0.001, vs. the Omnipod 6 phase in children 2-<6y and 6-<14y, respectively. No severe hypoglycemia or DKA events occurred. Conclusions These results demonstrate safety and strong efficacy potential of the next-generation Omnipod 6 algorithm in children with T1D as young as 2y.
AIMS:Beyond their glycaemic benefits, automated insulin delivery (AID) systems can provide psychosocial benefits for people with type 1 diabetes (T1D) and improve quality of life. In this study, we evaluated psychosocial outcomes in adults with T1D using the tubeless Omnipod® 5 AID System compared with sensor augmented pump (SAP) therapy. MATERIALS AND METHODS:As part of a 13-week multicentre, parallel-group, randomised controlled trial comparing intervention (tubeless AID) and control (SAP) groups (2:1), adults aged 18-70 years with T1D completed validated psychosocial questionnaires assessing health-related quality of life (European Quality of Life 5 Dimensions 3 Level Version [EQ-5D-3L] index score and visual analogue scale [VAS]), the impact of diabetes on quality of life (DAWN2 Impact of Diabetes Profile [DIDP]), sleep quality (Pittsburgh Sleep Quality Index [PSQI]), system usability (System Usability Scale [SUS]) and perceptions before and experiences after using AID systems (INsulin Dosing Systems: Perceptions, Ideas, Reflections and Expectations [INSPIRE]). RESULTS:The intervention group saw greater score improvements than the control group for all measures evaluated, including health-related quality of life (EQ-5D-3L VAS, p = 0.01; EQ-5D-3L index score, p = 0.002), impact of diabetes on quality of life (DIDP, p = 0.004), perceived system usability (SUS, p < 0.0001) and sleep quality (PSQI, p = 0.03). INSPIRE scores, determined only for the intervention group, were high at baseline and follow-up, suggesting positive perceptions of tubeless AID. CONCLUSIONS:This randomised controlled trial demonstrated that the use of a tubeless AID system improved psychosocial measures to a greater extent than SAP therapy. These results contribute to the growing body of evidence demonstrating that AID may improve quality of life and alleviate some of the burden associated with diabetes self-management in adults with T1D.